Facebook

Solutions to improve access to medicines and biomedical innovation through EU trade and R&D policy

The European Union’s (EU) free trade and research and development (R&D) policies promote excessive intellectual property (IP) protection. This approach jeopardises access to affordable, needed medicines and impedes needs-driven biomedical innovation.
Médecins Sans Frontières Access Campaign and our partners at HAI Europe and Oxfam are offering policy-makers seven straight-forward solutions that could transform harmful trade and R&D policy. By taking these solutions on board, the EU could enhance medicines access and pharmaceutical innovation in the EU and around the world.
DOWNLOAD THE DOCUMENT
Solutions to improve A2M and biomedical innovation.pdf
Page updated: 24 November 2014
↑ To top

Lives on the edge - patient needs are not driving medical research and development, and the result is millions of lives on the edge.